Skip to content
HomeLatest newsPersonal storiesWhy I’m proud to work at Johnson & Johnson—a “Top 60 Companies for Executive Women” award winner
Sandi NAFE blog

Why I’m proud to work at Johnson & Johnson—a “Top 60 Companies for Executive Women” award winner

Share Article
share to

At the beginning of my career, I used to look around and realize that I was the only woman in the room.

So today’s news that, for the fifth year, Johnson & Johnson has garnered a top 10 spot on the National Association for Female Executives (NAFE) “Top 60 Companies for Executive Women” list, has a special significance for me.

Not only am I humbled to be part of a company that prides itself on supporting and promoting a diverse workforce, but I’m also grateful for the many women and men who’ve created a culture that makes this recognition possible.

The reality is that Johnson & Johnson has a strong history of diversification in the workplace dating back to 1886. At that time, the United States was heavily resistant to accepting women in the workplace. It was also the year that Johnson & Johnson was founded by a group of 14 employees—eight of whom were women.

Read more about our first women employees

This unprecedented beginning set the foundation for our progressive culture, where employees are encouraged to challenge the status quo and take risks.

Today, we also know something those founders didn’t: A diverse workforce actually makes for a healthier, more successful business.

The fact is that women now make at least 80% of all healthcare decisions for their families, so it only makes sense that they have a prominent place at the table to help make the business decisions that can positively impact our consumers, patients and customers. And I’m thrilled to report that women now make up 34% of our corporate executive base, running businesses and creating innovative solutions each and every day.

In the last 20 years, our women’s resource group at Johnson & Johnson has grown to over 5,000 employees globally, and we’re collaborating with organizations, such as Fortune and Vital Voices, to expand our reach and provide more women with the resources they need to meet their full potential.

This year, we also rolled out a program that’s near and dear to me: STEM2D, which is designed to support and encourage both young girls and college-aged women to pursue careers in science, technology, engineering, math, manufacturing and design. These women are our future, so we need to bolster them.

Read more about STEM2D

I know we still have a ways to go, but I can sleep soundly at night knowing that we employ some of the most talented women in the world who are working to accelerate women’s leadership not only in our organization, but also around the world.

So thank you NAFE for recognizing these women—and thank you to all the employees who help make this company worth recognizing.

Sandi Peterson is Group Worldwide Chairman for Johnson & Johnson. Her portfolio includes the company’s global operating infrastructure, multiple consumer-facing businesses, and key enterprise initiatives designed to spur innovation and accelerate growth. She is at the forefront of Johnson & Johnson’s efforts to transform healthcare using technology and design-thinking to leverage its unique assets in innovative ways to create breakthrough solutions. Sandi has been named to Fortune magazine’s list of The Most Powerful Women three times, most recently being the 2015 list.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.